尼莫地平对蛛网膜下腔出血的临床治疗价值

Clinical Treatment Value of Nimodipine For Subarachnoid Hemorrhage

目的探讨尼莫地平对蛛网膜下腔出血的临床治疗价值。方法选取我院收治的蛛网膜下腔出血患者112例,将其随机分为观察组和对照组各56例。对照组患者给予常规治疗,观察组在对照组基础上给予尼莫地平进行治疗,比较两组临床疗效、并发症及预后情况。结果观察组患者治疗有效率、预后良好率分别为91.1%、58.9%,对照组分别为71.4%、30.4%,两组对比差异显著,具有统计学意义(P<0.01);观察组患者并发症发生率为12.5%,明显低于对照组的48.2%,两组比较差异有统计学意义(P<0.01)。结论尼莫地平治疗蛛网膜下腔出血临床效果显著,患者并发症少,预后效果好,值得推广。

Objective To investigate the clinical treatment value of nimodipine for subarachnoid hemorrhage. Methods 112 cases of patients with subarachnoid hemorrhage treated in our hospital were selected and randomly divided into observation group and control group, with 30 cases in each group. The control group received conventional therapy, while the observation group was given nimodipine combined with conventional therapy on the basis of control group. The clinical efficacy, complications and prognosis of two groups were compared. Results The effective rate and the good prognosis rate of the observation group were 91.1% and 58.9% respectively, higher than 71.4% and 30.4% of the control group, with significant difference （P 〈0.01）; the complication rate of the observation group was 12.5%, significantly lower than 48.2% of the control group, with statistical significant difference （P 〈0.01）. Conclusions The application of nimodipine in treating subarachnoid hemorrhage has significant clinical effect with fewer complications and good prognosis effect, which is worthy of promotion.